Paper Details

  1. Home
  2. Paper Details

Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS.

Author: , CornelJan H, EngelSamuel S, HolmanRury R, JakubonieneNeli, JosseRobert G, PetersonEric D, RiefflinAxel, StevensSusanna R, SuryawanshiShailaja, TankovaTsvetalina, WainsteinJulio

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study examined the incidence of diabetes-associated complications and the safety of sitagliptin in participants with chronic kidney disease (CKD) in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). The study found that participants with CKD had higher incidences of serious adverse events and diabetes complications than those without CKD. However, sitagliptin was generally well tolerated in participants with CKD, with no meaningful differences in safety outcomes observed between those with CKD assigned to sitagliptin or placebo. This suggests that sitagliptin may be a safe and effective treatment option for diabetes in patients with CKD.
Paper Details　
Original Abstract of the Article :
AIMS: To characterize the incidence of diabetes-associated complications and assess the safety of sitagliptin in participants with chronic kidney disease (CKD) in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). MATERIALS AND METHODS: For participants with baseline eGFR measur...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/dom.12983

データ提供：米国国立医学図書館（NLM）

Safety of Sitagliptin in Patients with Type 2 Diabetes

This research explores the challenging world of type 2 diabetes, a condition that can be like a desert oasis that's slowly drying up, with the body struggling to regulate its water supply. This study investigates the safety of sitagliptin, a medication used to treat type 2 diabetes, in individuals with chronic kidney disease, a condition that can further strain the body's water balance. It's like studying the impact of a prolonged drought on the oasis, exploring how to best manage the dwindling water resources.

Sitagliptin Generally Safe in Patients with CKD

The researchers found that sitagliptin was generally safe and well-tolerated in patients with type 2 diabetes and chronic kidney disease. It's like finding a new way to conserve water in the desert, ensuring the oasis can survive a prolonged drought. The study found that sitagliptin did not significantly increase the risk of diabetes complications in these patients.

Navigating Type 2 Diabetes with CKD

This research offers valuable information for those managing type 2 diabetes and chronic kidney disease. It suggests that sitagliptin can be a safe and effective treatment option for these patients, potentially helping them manage their blood sugar levels and prevent complications. However, it's essential to work closely with a healthcare professional to monitor for any potential side effects and to adjust treatment as needed.

Dr. Camel's Conclusion

This research delves into the challenges of type 2 diabetes, a condition that can be like a desert oasis that's slowly drying up. The study explores the safety of sitagliptin in patients with chronic kidney disease, offering hope for a more manageable journey through the desert of diabetes.
Date :
  1. Date Completed 2018-06-12
  2. Date Revised 2018-06-19
Further Info :

Pubmed ID

28432745

DOI: Digital Object Identifier

10.1111/dom.12983

Related Literature

Article Analysis
・Side Effects of sitagliptin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.